Oct. 8, 2021 -- The protection from Pfizer’s COVID-19 vaccine may begin to wane against infection after 2 months, but it still
prevents hospitalization and death for at least 6 months, according to two new studies published Wednesday in TheNew England Journal of Medicine. The new findings support what Pfizer, the CDC, and top health officials have said in recent weeks: Initial protection against getting the coronavirus itself may drop over time, but people who get the vaccine avoid the worst effects
of severe disease. In the first study, researchers in Qatar estimated vaccine efficacy against COVID-19 infection and severe, critical, or fatal cases between Jan. 1 and Sept. 5. They based the report on infections among 900,000 vaccinated people in Qatar. After the first Pfizer dose, protection against infection was “negligible” for the first 2 weeks but jumped to about 37% in the
third week. Protection then reached a peak of about 78% in the first month after the second dose. Efficacy fell gradually after that, with the decline speeding up after the fourth month. For some people who got the vaccine, protection dropped as low as 20% between 5 and 7 months after the second dose. “These
findings suggest that a large proportion of the vaccinated population could lose its protection against infection in the coming months, perhaps increasing the potential for new epidemic waves,” the researchers wrote. The effectiveness against symptomatic infection was higher than the effectiveness against asymptomatic infection, but both rates waned over time, the researchers wrote. A similar pattern was seen for the different variants, including the Beta and Delta variants. Effectiveness
against severe, critical, and fatal COVID-19 cases increased to 66% by the third week after the first dose and reached 96% in the first 2 months after the second dose. The protection lasted at this level for about 6 months. “Protection against SARS-CoV-2 infection appeared to wane rapidly following its peak after the second dose, but protection against hospitalization and death
persisted at a robust level for six months after the second dose,” the researchers wrote. In the second study, researchers in Israel looked at COVID-19 antibodies among more than 4,800 health care workers who were tested regularly after vaccination. Among those, 20 had breakthrough infections. The research team found that the level of antibodies circulating in the blood decreased at a consistent rate over 6 months. The level of neutralizing antibodies, which correlates with protection, decreased rapidly in the first 3 months but then slowly declined after that. Six months after the second dose, neutralizing antibodies were substantially lower among men than women. They were also lower for people ages 65 and older and those with weak immune systems. Neutralizing antibodies were significantly higher in those who had a body mass index of 30 or above. But the researchers said it’s unclear whether the higher level is more protective and whether vaccinated obese people face higher or lower risks for breakthrough infections. “As this pandemic continues to evolve, the importance of determining immune correlates of protection after vaccination becomes clearer,” the researchers wrote. “Strategies to prolong host immunity need to be evaluated in order to protect the population against SARS-CoV-2 and its variants.” How long does it take to build immunity after getting a Covid-19 vaccine?Immunity takes a while to build up. If you had your first Covid-19 vaccine dose yesterday, then you are not protected yet. Your body needs to spend time responding to the vaccination before it can produce an effective immune response. It seems that some protection starts to appear about 2 weeks after the first dose, and then this increases over time. But after a longer time – we aren’t yet sure how long – this protection is likely to start to fade again. So you will need a second booster dose to make sure your immune system can consolidate this protection for the long term. The benefits of the second dose start to appear after about 1 to 2 weeks. And there are different degrees of protection: against death, against needing to go to hospital, against getting ill, and against getting infected at all. A round-up of evidence from around the world, by Public Health England, finds that one dose of the Pfizer-BioNTech or Oxford-AstraZeneca vaccines is fairly good at preventing infection and illness, and better at preventing hospitalisation or death. After a second dose, protection increases further, although at the moment there’s more evidence on second doses of Pfizer-BioNTech than Oxford-AstraZeneca. How long after the first dose should you have the second dose?The UK introduced its policy of leaving a 12-week gap between Covid-19 vaccine doses at the end of December 2020. This is at the top end of the range recommended by the makers of the Oxford-AstraZeneca vaccine (4 to 12 weeks) but is much longer than recommended for the Pfizer-BioNTech vaccine (3 weeks). Leaving the second dose too late is risky, because the effects of the first dose might start to weaken. But giving the second dose too soon is also risky, because your immune system needs time to fully react to the first dose so that it can then get maximum benefit from the second. For the new Covid-19 vaccines, we don’t yet know what the ideal gap is – it takes time to test this. But the evidence is positive about longer delay. For the Oxford-AstraZeneca vaccine, data from clinical trials suggests that a single dose gives good protection against illness for more than 12 weeks, and that the booster effect of the second dose is stronger when the gap between doses is longer. For the Pfizer-BioNTech vaccine, we have less specific evidence on this from clinical trials. But real-world observation is showing that first doses maintain their strong benefits for longer than the initial 3 weeks. Public Health England monitors illness rates among adults who have and haven’t been vaccinated, and it reports that protection from the first dose of Pfizer-BioNTech grows over time, holding up very well 8-9 weeks after the jab. But there are some signs that this protection may drop a little after 10 weeks. For Oxford-AstraZeneca, protection from the first dose stays strong with no sign of decline. Can you still get ill with Covid-19 after vaccination?The new vaccines are very good, but they’re not perfect, and no vaccine works perfectly for everybody. The highest estimates of their peak efficacy are above 90%, but not quite 100%. After you’re vaccinated, it is possible that you could catch Covid-19. But if you do get ill, it’s much less likely to be severe and you’re much more likely to recover without needing to be hospitalised. Have you read?
Remember, immunity takes weeks to properly develop after getting your first dose, so during that time you may still be at some risk. There’s also the danger of new coronavirus variants emerging that might be able to avoid the vaccines’ effects. For example, people have been concerned about the delta variant, first identified in India but now spreading in many countries. Public Health England has looked at how effective the Pfizer-BioNTech and Oxford-AstraZeneca vaccines are against this variant. So far, it seems that the first dose of either vaccine is less likely to stop the variant from causing illness – but protection from the second dose is much higher. Scientists are already looking at ways to adjust the vaccines to cope with such variants, so in the future we might need occasional booster jabs to keep us protected. We might even need boosters at some point regardless of any variants, as it’s possible that the protection might fade over longer periods. Long-term monitoring of vaccine effectiveness will be needed to help us understand this. Do the vaccines prevent you from spreading coronavirus?We know that vaccination can stop you from getting seriously ill if you catch the virus, but an early worry was that it might not stop you from carrying the virus and spreading it to others. Now, evidence is coming in showing that vaccination can also reduce the spread of infection. According to Public Health England’s review of evidence, the Pfizer-BioNTech and Oxford-AstraZeneca vaccines both offer moderate protection against infection from the first dose. A second dose of Pfizer-BioNTech increases this protection further, but there isn’t yet enough data on whether a second dose of Oxford-AstraZeneca does the same. Why did the UK decide to extend the gap between doses?UK cases of Covid-19 were surging last December, along with hospitalisations and deaths, and there was a risk that the NHS could be overwhelmed. In light of this, health authorities decided that it would be better to give the protection of a first dose to as many people as possible, as fast as possible. That meant delaying second doses, on the grounds that they would add only limited extra protection to people who already had significant immunity from their first dose. This policy was recommended by the independent experts on the Joint Committee on Vaccination and Immunisation – an independent expert group that advises the UK health departments – and the UK’s Chief Medical Officers agreed. Ideally, researchers would run a set of clinical trials to compare different dosing schedules and then authorities would make policy based on plenty of solid data. But in the face of a public health emergency, waiting would have cost lives. The decision was based on limited data from the vaccine trials in 2020, coupled with expert judgement about how vaccines generally work. Evidence that has appeared since then is, so far, vindicating that decision. In mid-May, in response to the spread of the delta variant, the UK slightly changed its policy again. It is now recommending that people in the highest-risk groups should get their second doses sooner, after a gap of about 8 weeks. The government thinks that the short-term extra protection from these second doses may be important if case numbers increase sharply. Which other countries are delaying second doses?In early March, Germany changed its policy to leave a 6-week gap between doses of Pfizer-BioNTech and 12 weeks between doses of Oxford-AstraZeneca. Canada has gone even further, changing official guidance to support a 4-month gap. What about 'mixing and matching'?There is no evidence yet on whether switching vaccines between doses can make any difference, but some immunisation programmes for other diseases do this because the results are better. There are already trials underway to test whether this might work for the Covid-19 vaccines. In the meantime, the UK government says that people should get a second dose of the same vaccine as their first dose, as do other governments around the world. However, if supplies of that vaccine are unavailable, or information has been lost on which the first dose was, the UK guidance is that it may be better to give a dose of whichever is available rather than no second dose at all. What happens next?As the vaccine rollout continues, we need to keep reducing the spread of the virus by following guidelines on wearing masks, washing hands and avoiding face-to-face contact wherever possible. This applies even after receiving the first dose, because immunity takes time to build up. Scientists will need to keep monitoring the appearance of new variants across the world, and devise ways to modify the vaccines if needed. Finally, it is crucial to make sure vaccination is rolled out speedily and equitably across the globe, not just in the UK and other rich countries. The more people worldwide who remain exposed to the virus, the more opportunity it will have to mutate into a more harmful form. In a pandemic like this, the interests of any one country merge together into the interests of the whole human race. WEBSITEThis article was originally published by Wellcome under Creative Commons Attribution 2.0 UK on 11 June 2021.
|
How protective is one dose of pfizer
Copyright © 2024 toptenid.com Inc.
